抗胆固醇抑郁症:一个病例报告显示,认知和功能得到改善,戒断后的不良影响最小
Carina Lundby1,2,3,4, Barbara Farrell1,5,6, Amanda Wilson1,5
1Geriatric Day Hospital, Bruyère Continuing Care, Ottawa, Canada.
British journal of clinical pharmacology
|May 2, 2024
概括
在停止服用这些药物后,抗胆固醇诱导的认知障碍可能会改善. 这项案例研究强调了多西戒断期间抗胆固醇不良药物戒断事件 (ADWE) 的最小值,这表明抑郁可能是可行的.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 临床神经学 临床神经学
背景情况:
- 抗胆固醇药物经常被处方,但可能导致认知障碍.
- 由于未知的不良药物戒断事件 (ADWE) 风险,处方抗胆固醇药物具有挑战性.
- 关于抗胆固醇ADWE的发生率,时间和严重程度的数据有限.
研究的目的:
- 在停止服用强抗胆固醇药物后,报告一个显著认知改善的病例.
- 评估在药物停用期间发生抗胆固醇不良药物戒断事件 (ADWE) 的风险.
- 为安全和自信的抗胆固醇抑郁药物处方策略提供信息.
主要方法:
- 一个76岁的老妇人的病例报告.
- 停止长期使用多克塞 (一种强烈的抗胆固醇药物).
- 减少另一种潜在抗胆固醇药物的剂量.
主要成果:
- 患者突然停止了多克西平,没有计划的逐渐减少.
- 没有观察到严重的抗胆固醇不良药物戒断事件 (ADWE).
- 停药后,人们注意到认知功能的显著改善.
结论:
- 抗胆固醇诱导的认知障碍在药物停止后可能是可逆的.
- 在这种情况下,突然停止多西并没有导致严重的ADWE.
- 需要进一步的研究来了解抗胆固醇ADWE对于安全的抑郁症.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
121
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
121
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
662
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
662
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Antidepressant Drugs: MAOIs and Other Agents
227
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
227
Psychosis: Goals of Pharmacotherapy
124
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
124


